ArticleVascular medicine (London, England)2013
Peripheral artery disease and risk of cardiovascular events in patients with coronary artery disease: insights from the Heart and Soul Study.
Article in Vascular medicine (London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04661644 (A Phase 1/2a Clinical Trial to Evaluate the Efficacy and Safety of Allogenic Adipose Tissue-derived Mesenchymal Stem Cell Clusters in Patients with Critical Limb Ischemia), which is not on this map. Cited by 72 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1/2a Clinical Trial to Evaluate the Efficacy and Safety of Allogenic Adipose Tissue-derived Mesenchymal Stem Cell Clusters in Patients with Critical Limb Ischemia
Who cites it
72 citing papers in PubMed, 166 citations in OpenAlex.
- Using precision medicine methods to identify disease stages for chronic limb-threatening ischemia in participants of the BEST-CLI trial.Journal of vascular surgery · 2026Trial
- Predictors of change in omega-3 index with fish oil supplementation in peripheral artery disease.The Journal of surgical research · 2017Trial
- Efficacy of brief behavioral counselling by allied health professionals to promote physical activity in people with peripheral arterial disease (BIPP): study protocol for a multi-center randomized controlled trial.BMC public health · 2016Trial
- Short-Term, High-Dose Fish Oil Supplementation Increases the Production of Omega-3 Fatty Acid-Derived Mediators in Patients With Peripheral Artery Disease (the OMEGA-PAD I Trial).Journal of the American Heart Association · 2015Trial
- Atherosclerosis Progression Evaluation in Coronary Arteries by Computed Tomography Compared to Peripheral Vessels Using 3D Ultrasonography.Journal of clinical medicine · 2026Article
- The Equality Health-CVD intervention: protocol for a feasibility study of a home-based multi-component cardiovascular support intervention.Pilot and feasibility studies · 2026Article
- Too much, too little, or just right: Tailoring postrevascularization antithrombotic therapy in PAD versus CAD when one size does not fit all.Vascular medicine (London, England) · 2026Article
- Clinical Outcomes of Balloon-Only Venous Arterialization for Chronic Limb-Threatening Ischemia After Failed or Unfeasible Revascularization.Cardiovascular and interventional radiology · 2026Article
- Single vs. dual antiplatelet therapy in patients with severe peripheral arterial disease undergoing transcatheter aortic valve implantation: insights from the Hostile registry.European heart journal. Cardiovascular pharmacotherapy · 2025Observational
- Assessment of Cervicocephalic-Peripheral Atherosclerotic Burden Improves Prognostic Stratification in Patients with Ischemic Cerebrovascular Disease.Journal of clinical medicine · 2025Article
- Beyond Blood Sugar: A Scoping Review of GLP-1 Receptor Agonists in Cardiovascular Care.Cardiology and therapy · 2025Review
- Investigation of Growth Differentiation Factor 15 as a Prognostic Biomarker for Major Adverse Limb Events in Peripheral Artery Disease.Journal of clinical medicine · 2025Article
- Growth Differentiation Factor 15 Predicts Cardiovascular Events in Peripheral Artery Disease.Biomolecules · 2025Article
- The Prognostic Potential of Insulin-like Growth Factor-Binding Protein 1 for Cardiovascular Complications in Peripheral Artery Disease.Journal of cardiovascular development and disease · 2025Article
- Interferon Gamma and Tumor Necrosis Factor Alpha Are Inflammatory Biomarkers for Major Adverse Cardiovascular Events in Patients with Peripheral Artery Disease.Biomedicines · 2025Article
- Matrix Metalloproteinases 7 and 10 Are Prognostic Biomarkers for Systemic Cardiovascular Risk in Individuals with Peripheral Artery Disease.Biomolecules · 2025Article
- Association of Hepatocyte Growth Factor and Angiopoietin-2 with Systemic Cardiovascular Risk in Patients with Peripheral Artery Disease.Journal of clinical medicine · 2025Article
- The role of TyG index in predicting low left ventricular ejection fraction after acute coronary syndrome.Biomarkers in medicine · 2025Article
- Serum Trimethylamine N-Oxide Levels as a Predictor of Peripheral Arterial Disease in Kidney Transplant Recipients.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- Gender differences in the association between the triglyceride-glucose index and peripheral artery disease in vascular surgery inpatients aged 50 and above: a retrospective cross-sectional study.Frontiers in endocrinology · 2025Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Among patients with coronary artery disease (CAD), those with peripheral artery disease (PAD) have a greater vulnerability to cardiovascular (CV) events than those with CAD alone. In a prospective cohort study of patients with CAD, we evaluated potential mechanisms that might explain the adverse CV outcomes associated with PAD. We performed a prospective cohort study of 1018 patients with stable CAD who were recruited from 2000 to 2002. Incident symptomatic PAD events were adjudicated during a follow-up period of 7.2 ± 2.6 years. We used Cox proportional hazards models to evaluate the association between incident symptomatic PAD events and subsequent risk of CV events or death. Models were adjusted for demographics, traditional risk factors, inflammation, insulin resistance and health behaviors. Among the 1018 patients, 50 patients who did not report a history of PAD at baseline suffered incident symptomatic PAD events during the follow-up period. Those patients had a higher risk of subsequent CV events and death compared to those who did not develop PAD. After adjustment for traditional risk factors, symptomatic PAD events remained associated with a 70% increased risk of subsequent CV events (adjusted HR 1.7; 95% CI 1.0, 2.9; p = 0.04) and an 80% increased risk of death (adjusted HR 1.8; 95% CI 1.2, 2.7; p = 0.006). Inflammatory biomarkers were the strongest risk factor contributing to the excess risk. In a contemporary cohort of patients with CAD, incident symptomatic PAD events were associated with an increased risk for subsequent CV events. The increased vulnerability to CV events was partially explained by shared CV risk factors and inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.